Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
Zontivity (vorapaxar) for the Reduction of Thrombotic Cardiovascular Events - Clinical Trials Arena
Vorapaxar - an overview | ScienceDirect Topics
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018
![Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC](https://www.trc-canada.com/prod-img/V758202.png "Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC")
Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC
![PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c4d402004bb1cd7f7142aa35447751937911b5ff/2-Figure1-1.png "PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar")
PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar
A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivity™) | SpringerLink
Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
Vorapaxar - Wikipedia
Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients? | tctmd.com
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction | tctmd.com
Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial - The Lancet HIV
Vorapaxar, a Platelet Thrombin Receptor Antagonist, in Acute Coronary Syndromes Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees. - ppt download
Chemical structure of vorapaxar. | Download Scientific Diagram
The net clinical benefit of vorapaxar (CV death, MI, stroke or GUSTO... | Download Scientific Diagram
Vorapaxar - Wikipedia
Vorapaxar in the Secondary Prevention of Atherothrombotic Events | NEJM
Vorapaxar | Uses, Brand Names, Mechanism Of Action
Vorapaxar phase III program. (a) TRA-CER design and (b) TRA-2P design | Download Scientific Diagram
Vorapaxar - wikidoc
